Michalis Mastri
Overview
Explore the profile of Michalis Mastri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
506
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shi Y, McKenery A, Dolan M, Mastri M, Hill J, Dommer A, et al.
EMBO Rep
. 2024 Dec;
26(2):521-559.
PMID: 39663510
Therapeutic inhibition of programmed cell death ligand (PD-L1) is linked to alterations in interferon (IFN) signaling. Since IFN-regulated intracellular signaling can control extracellular secretory programs in tumors to modulate immunity,...
2.
Dolan M, Shi Y, Mastri M, Long M, McKenery A, Hill J, et al.
Mol Cancer Ther
. 2024 Jun;
:OF1-OF20.
PMID: 38896060
Tyrosine kinase inhibitors (TKIs) that block the vascular endothelial growth factor receptors (VEGFRs) not only disrupt tumor angiogenesis but also have many unexpected side effects that impact tumor cells directly....
3.
Benzekry S, Mastri M, Nicolo C, Ebos J
PLoS Comput Biol
. 2024 May;
20(5):e1012088.
PMID: 38701089
Clinical trials involving systemic neoadjuvant treatments in breast cancer aim to shrink tumors before surgery while simultaneously allowing for controlled evaluation of biomarkers, toxicity, and suppression of distant (occult) metastatic...
4.
Boland P, Ebos J, Attwood K, Mastri M, Fountzilas C, Iyer R, et al.
JNCI Cancer Spectr
. 2024 May;
8(3).
PMID: 38697618
Background: Nintedanib is a tyrosine kinase inhibitor with efficacy in bevacizumab-resistant colorectal cancer models. This phase I/II study evaluated the recommended phase II dose and efficacy of nintedanib and capecitabine...
5.
Dolan M, Shi Y, Mastri M, Long M, McKenery A, Hill J, et al.
Mol Cancer Ther
. 2024 May;
PMID: 38690835
Tyrosine kinase inhibitors (TKIs) that block the vascular endothelial growth factor receptors (VEGFRs) disrupt tumor angiogenesis but also have many unexpected side-effects that impact tumor cells directly. This includes the...
6.
Shah S, Gillard B, Wrobel M, Karasik E, Moser M, Mastri M, et al.
Front Oncol
. 2023 Feb;
13:1120329.
PMID: 36816919
Introduction: Bladder cancer is a heterogenous disease and the emerging knowledge on molecular classification of bladder tumors may impact treatment decisions based on molecular subtype. Pre-clinical models representing each subtype...
7.
Torres-Estay V, Mastri M, Rosario S, Fuenzalida P, Echeverria C, Flores E, et al.
Cancers (Basel)
. 2022 Oct;
14(19).
PMID: 36230673
The survival of patients with solid tumors, such as prostate cancer (PCa), has been limited and fleeting with anti-angiogenic therapies. It was previously thought that the mechanism by which the...
8.
Omole E, Aijaz I, Ellegate Jr J, Isenhart E, Desouki M, Mastri M, et al.
Cancers (Basel)
. 2022 Oct;
14(19).
PMID: 36230652
Like BRCA2, MAGEC3 is an ovarian cancer predisposition gene that has been shown to have prognostic significance in ovarian cancer patients. Despite the clinical significance of each gene, no studies...
9.
Ellegate Jr J, Mastri M, Isenhart E, Krolewski J, Chatta G, Kauffman E, et al.
Cancers (Basel)
. 2022 Feb;
14(3).
PMID: 35158998
Rare variants in MAGEC3 are associated with BRCA negative, early-onset ovarian cancers. Given this association, we evaluated the impact of MAGEC3 protein expression on prognosis and transcription. We quantified normal...
10.
Mastri M, Ramakrishnan S, Shah S, Karasik E, Gillard B, Moser M, et al.
Am J Clin Exp Urol
. 2022 Jan;
9(6):416-434.
PMID: 34993263
The evolving paradigm of the molecular classification of bladder cancer requires models that represent the classifications with less heterogeneity. Robust transcriptome based molecular classifications are essential to address tumor heterogeneity....